Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma

This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Carfilzomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving teclistamab and pomalidomide may be safe, tolerable and improve response by lowering myeloma cells to undetectable levels when compared to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with relapsed multiple myeloma.

开始日期2027-04-12

申办/合作机构

National Cancer Institute

NCT07831122

/ Not yet recruiting临床1期IIT

An Open-Label Phase Ib, Multicenter Study To Evaluate The Safety And Efficacy Of Belantamab Mafodotin Plus Cevostamab And Pomalidomide In Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.

开始日期2026-12-01

申办/合作机构

GSK Plc

NCT07728188

/ Not yet recruiting临床3期

A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)

Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide.
Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide.
Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2026-11-30

申办/合作机构

AbbVie, Inc.

100 项与泊马度胺相关的临床结果

登录后查看更多信息

100 项与泊马度胺相关的转化医学

登录后查看更多信息

100 项与泊马度胺相关的专利（医药）

登录后查看更多信息

2,387

项与泊马度胺相关的文献（医药）

2026-12-01·JOURNAL OF MOLECULAR MEDICINE-JMM

Anti-myeloma activity of the CXCR4 antagonist WZ811

Article

作者: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka

Abstract:

The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G 0 /G 1 phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.

Key messages:

WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.

2026-09-01·BIOORGANIC CHEMISTRY

Potent and isoform-selective PARP1 degraders for the treatment of BRCA-deficient cancers

Article

作者: Guo, Rongrong ; Xue, Jiayu ; Sun, Hui ; Liang, Yan ; Hu, Yang ; Xu, Xiaowei ; Ren, Jun ; Li, Bin

PARP inhibitors leverage synthetic lethality in BRCA-mutant tumors, but resistance and PARP2- associated hematological toxicities limit their clinical utility. In this study, a series of novel PROTAC degraders utilizing the highly selective PARP1 inhibitor AZD5305 as the recruiting moiety was reported. Through linker optimization, CPP-13, a pomalidomide-based degrader with a 13-atom linker, was confirmed as the lead compound. CPP-13 exhibited potent PARP1 degradation potency (DC₅₀ = 0.48 nM, D_max = 90%) and robust antiproliferative activity (IC₅₀ = 3.0 nM) in BRCA-deficient cells. Mechanistic investigations confirmed that CPP-13 functions through a CRBN-dependent ubiquitin-proteasome pathway, maintaining high isoform selectivity for PARP1 over PARP2. Furthermore, CPP-13 treatment was associated with γH2AX accumulation and selective growth inhibition in BRCA-deficient breast and pancreatic cancer models. Overall, CPP-13 serves as a valuable chemical tool and demonstrates the feasibility of selective PARP1 degradation using an AZD5305-based PROTAC strategy. Further optimization will be required to improve its pharmacokinetic properties and enable in vivo efficacy evaluation.

2026-09-01·Clinical Lymphoma Myeloma & Leukemia

Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management

Review

作者: Mian, Hira ; Lonial, Sagar ; Cani, Lorenzo ; Mateos, Maria Victoria ; Trudel, Suzanne ; Voorhees, Peeter ; Popat, Rakesh ; Terpos, Evangelos ; Usmani, Saad ; Mina, Roberto ; Dhakal, Binod ; Nooka, Ajay ; Richter, Joshua

Belantamab mafodotin (belamaf) is an antibody-drug conjugate targeting B-cell maturation antigen on plasma cells. The phase III DREAMM-7 and DREAMM-8 trials, in which belamaf was combined with bortezomib-dexamethasone or pomalidomide-dexamethasone, respectively, showed significantly higher overall response and measurable residual disease negativity rates for belamaf-combinations as compared to standard-of-care triplets, as well as improved longitudinal outcomes. Collectively, the results of DREAMM-7 and DREAMM-8 have established these regimens as a treatment option for patients with relapsed or refractory multiple myeloma, leading to regulatory approval of belamaf in combination with bortezomib by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and in combination with pomalidomide by the EMA. Belamaf is associated with a distinctive spectrum of eye-related adverse events (AEs), largely attributable to the off-target effect of its cytotoxic payload, the monomethyl auristatin F (MMAF). Despite their frequent occurrence, eye-ocular AEs have been shown to be reversible, and have rarely led to belamaf discontinuation. Multiple dosing strategies and schedules of the drug have been explored in phase I/II and III trials in an attempt to optimize its efficacy while limiting ocular toxicity. In this review, we summarize the current literature regarding efficacy and safety of belamaf, with a focus on ocular toxicity. We discuss current recommendations for eye-related AE assessment and emerging strategies for dose optimization and toxicity management, aiming to maximize therapeutic benefit while minimizing ocular toxicity.

1,701

项与泊马度胺相关的新闻（医药）

2026-09-22

·淋白春晓

ORR 89.5%！自主创新BCMA×CD3双特异性抗体GR1803，已获批上市，治疗多发性骨髓瘤患者

点击蓝字关注我们特别福利：通过平台指定基因检测公司进行基因检测并成功入组临床的患者，基因检测费用可以全额退款（限额5000元），具体请咨询平台医生（联系方式见文末）。肿瘤新药信息群每日公布新药信息专业肿瘤科医生免费咨询扫码免费加群温馨提示更多新药免费临床试验信息，请访问下方网站： www.onc123.com 说明：网站内可以直接按病种检索，无需爬楼梯！复制上方网址，在浏览器内即可打开访问适应症：多发性骨髓瘤数据来源：国家药监局药物临床试验登记与信息公示平台（chinadrugtrials.org.cn）、2025 ASH 年会 GR1803 I 期研究（数据截止 2025-07-01，n=60）摘要复发或难治性多发性骨髓瘤患者在多线治疗后有效选择十分有限。重庆智翔金泰自主研发的 GR1803（纬利妥米单抗）是一款靶向 BCMA/CD3 的双特异性抗体，目前 III 期临床研究正在开展，头对头比较 GR1803 与达雷妥尤单抗+泊马度胺+地塞米松治疗既往接受过 1–3 线治疗的复发/难治性多发性骨髓瘤，在全国多中心推进。在 2025 年 ASH 年会公布的 I 期研究中，GR1803 在复发/难治性多发性骨髓瘤患者中客观缓解率达到 89.5%，并显示出较高的微小残留病（MRD）阴性率。药物背景与作用机制 GR1803 是一款靶向 BCMA 与 CD3 的双特异性抗体，采用非对称亲和力设计：对 BCMA 的亲和力比对 CD3 高两个数量级，在精准募集并激活 T 细胞杀伤表达 BCMA 的骨髓瘤细胞的同时，最大限度减少 CD3 过度激活带来的非特异毒性。 BCMA 在恶性浆细胞表面高表达，是多发性骨髓瘤的成熟靶点；GR1803 通过桥接 T 细胞与肿瘤细胞，发挥 T 细胞介导的定向杀伤作用。创新优势与临床定位双靶点 T 细胞衔接：同时结合 BCMA 与 CD3，将细胞毒性 T 细胞定向至骨髓瘤细胞非对称亲和力设计：降低 CD3 介导的非特异性激活与毒性 I 期数据优异：2025 ASH 公布研究中 ORR 89.5%，RP2D 队列 MRD 阴性率 54.2% 头对头 III 期：直接对照达雷妥尤单抗+泊马度胺+地塞米松，验证优效潜力监管认可：已被 CDE 纳入突破性治疗品种与优先审评已获批上市：8 月 27 日，纬利妥米单抗在国内获批上市，获批适应症为用于既往至少接受过三线治疗（包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤成人患者。已公布的临床数据 2025 年 ASH 年会公布的 GR1803 I 期研究数据（数据截止 2025-07-01，共入组 60 例复发/难治性多发性骨髓瘤患者，其中 57 例至少接受一次疗效评估）：人群ORR其他指标总体可评估人群（57 例）89.5%（51/57）—180 μg/kg 推荐剂量（RP2D，48 例）87.5%（42/48）≥VGPR 70.8%≥CR 37.5%;MRD 阴性 54.2%基线合并髓外病变（EMM，24 例）83.3%（20/24）对髓外病变同样有效上述为 GR1803 I 期研究结果;RP2D 队列中 ≥3 级治疗相关不良事件约 97.9%，常见为低钾血症、细胞因子释放综合征（CRS）、中性粒细胞与血小板计数降低等，总体耐受性良好且疗效持久。本次登记要点试验名称：一项在既往接受过1-3线治疗（包括来那度胺和蛋白酶体抑制剂）的复发/难治性多发性骨髓瘤受试者中比较GR1803注射液与达雷妥尤单抗+泊马度胺+地塞米松的疗效和安全性的多中心、开放、随机Ⅲ期临床试验适应症：复发或难治性多发性骨髓瘤（既往 1–3 线治疗）研究设计：III 期、随机、开放、对照给药方式：皮下/静脉给药，按研究方案递增至维持剂量（具体以方案为准）核心在研药物：GR1803 注射液（纬利妥米单抗）——智翔金泰自主研发的 BCMA/CD3 双特异性抗体申办方：重庆智翔金泰生物制药股份有限公司 / 智翔（上海）医药科技有限公司研究状态：进行中，全国多中心核心入组参考可以考虑加入年龄 18 周岁及以上根据 IMWG 标准诊断为多发性骨髓瘤既往接受过 1–3 线抗骨髓瘤治疗，且包含一种蛋白酶体抑制剂与来那度胺（仅 1 线者须为来那度胺难治）近一次治疗后记录到疾病稳定或进展证据筛选期存在可测量的血液学病灶（如血清 M 蛋白、尿 M 蛋白或血清游离轻链异常）暂不适合加入（部分）既往接受过任何 BCMA 靶向治疗对既往抗 CD38 靶向治疗难治或不耐受对泊马度胺难治或不耐受淀粉样变性、浆细胞白血病、POEMS 综合征或华氏巨球蛋白血症多发性骨髓瘤中枢神经系统受累具体入组资格由研究医生结合完整病历资料评估。咨询与报名报名方式：13022079715（手机微信同号）在线问诊 Doctor 肿瘤专科医生免费在线问诊我们的优势最后，我们强烈建议选择我们的渠道进行临床报名，相比其他招募渠道，我们有更完整的临床项目库，我们了解病情、了解各个招募项目的入排要求、更了解项目之间的合理搭配，能让患者大大增加连续入组的成功率！通过我们报名的临床，入组成功率更高、获益更大! 欢迎在其他渠道报名失败的患者和家属联系我们！目前有肺癌、肝癌、肾癌、胃癌、肠癌、胰腺癌、妇瘤、泌尿肿瘤、血液肿瘤......等几乎涵盖所有癌种的临床试验正在招募患者！而且每一个在我们这里报名的患者，通过平台进行基因检测并成功入组患者，全额退还基因检测费用。平台福利福利一、免费基因检测（限初诊或耐药肿瘤患者，生活能自理且有意愿参加临床试验）免费基因检测长按左侧二维码报名福利二、免费临床试验入组免费临床试验入组长按左侧二维码报名基因免费基因检测咨询 18024087280 （微信手机同号）长按上方二维码咨询肿瘤免费临床试验入组咨询 13022079715 （微信手机同号）长按上方二维码咨询 #临床试验#GR1803#纬利妥米单抗#多发性骨髓瘤

2026-09-22

·药研苑

欧盟CHMP推荐特立妥单抗用于难治性多发性骨髓瘤二线治疗

药品营销避坑”试读：药品导入期管理视频课（试听）药品生命周期管理（案例）药品立项需要注意什么（案例） 2026年9月18日强生Johnson & Johnson宣布，欧洲药品管理局（EMA）欧洲药品人用药品委员会（CHMP）建议批准特立妥单抗的新增适应症，用于既往接受过至少一线治疗的复发或难治性多发性骨髓瘤成人患者。本次获得CHMP推荐特立妥单抗新增适应症基于3期临床试验MajesTEC-9的中期分析结果。MajesTEC-9研究共纳入593名既往接受过一至三线（包括抗CD38单克隆抗体和来那度胺Lenalidomide）治疗的复发或难治性多发性骨髓瘤成人患者。入组患者随机接受特立妥单抗，或研究者选择的治疗方案（泊马度胺Pomalidomide+硼替佐米Bortezomib+地塞米松Dexamethasone，或卡非佐米Carfilzomib++地塞米松Dexamethasone）。中期分析显示，特立妥单抗组和研究者选择治疗方案组18个月无进展生存（PFS）率分别为69.8%和26.9%（HR, 0.29; 95% CI, 0.23–0.38; P<0.001）；特立妥单抗组和研究者选择治疗方案组≥完全缓解的比例分别为65.9%和16.8%（P<0.001），预估18个月总生存（OS）率分别为79.2%和68.6%（HR, 0.60; 95% CI, 0.43–0.83; P=0.002）。在安全性方面，特立妥单抗组和研究者选择治疗方案组3-4级不良事件的发生率分别为84.9%和76.3%，5级不良事件的发生率分别为6.5%和3.5%。特立妥单抗组细胞因子释放综合征的发生率为66.0%，主要为1-2级。特立妥单抗组免疫效应细胞相关神经毒性综合征发生率为4.1%，3-4级感染的发生率为41.6%。研究者选择治疗方案组3-4级感染的发生率为29.0%（Cyrille Touzeau., 2026）。特立妥单抗（Teclistamab）为靶向BCMA/CD3的IgG4双特异性T细胞衔接器抗体，Etentamig通过结合多发性骨髓瘤细胞的BCMA以及T细胞的CD3，激活并引导T细胞杀伤多发性骨髓瘤细胞。特立妥单抗已在国内获批：用于既往接受过至少三线治疗（包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤成人患者。目前国内获批上市的靶向BCMA/CD3双特异性抗体药物，除包括特立妥单抗（Teclistamab）外，还包括埃纳妥单抗（Elranatamab）和纬利妥米单抗（Velinotamig），三者适应症相同。推荐指数：★★★ 推荐原因：特立妥单抗用于复发或难治性多发性骨髓瘤的二线治疗，将实现治疗方案前移。个人观点，仅限参考。相关阅读：重磅布地奈德福莫特罗吸入粉雾剂（Ⅱ）臣邦医药首仿获批科伦药业雌二醇地屈孕酮片首仿获批礼来塞普替尼新剂型片剂获批上市百傲万里软骨发育不全治疗药物伏索利肽获批上市罗氏CD20/CD3双抗莫妥珠滤泡性淋巴瘤3期试验达到终点百时美施贵宝氘可来昔替尼银屑病关节炎3期试验2年研究发布云顶新耀中重度溃疡性结肠炎治疗药物艾曲莫德申请本地化生产康乃德乐德奇拜哮喘急性加重2期临床试验未能达到主要终点他雷替尼用于ROS1+非小细胞肺癌2期试验新汇总分析数据发布 RNA剪接调节剂SKY-0515亨廷顿病1/2期试验最终结果发布博志研新重新提交BCM347（氨溴索口溶膜）上市申请正大天晴双抗ADC(TQB2102)申请上市用于HER2低表达乳腺癌正大天晴IL-4Rα单抗TQH2722申请上市用于中重度特应性皮炎埃万妥一线治疗Ex20ins晚期NSCLC三期试验总生存期结果发布相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。

2026-09-22

·BioSpace

GSK Canada and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Blenrep for the treatment of relapsed or refractory multiple myeloma

MISSISSAUGA, ON , Sept. 22, 2026 /CNW/ -- GSK Canada announced today that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for Blenrep (belantamab mafodotin for injection) for the treatment of adult patients with relapsed or refractory multiple myeloma. The LOI with the pCPA is an important step towards securing public drug plan coverage for Blenrep across Canada. Following the finalization of funding agreements with each of the provinces and territories, eligible patients will gain publicly funded access to Blenrep as a new treatment option for relapsed or refractory multiple myeloma. "This agreement moves us closer to ensuring that eligible patients can access new treatment options for a disease that often relapses and requires multiple lines of therapy," said Tina Graves, General Manager, GSK Canada. "Our priority now is to work with provinces and territories to translate the pCPA outcome into access for patients. Multiple myeloma has seen great innovation in recent years, yet there remains a need for effective, practical treatments that are accessible across all treatment settings and that help reduce the day-to-day impact of care on patients and their families." "People affected by this rare and complex blood cancer often face repeated rounds of treatment, ongoing symptoms and frequent hospital visits, which can be challenging for patients in urban settings as well as those in rural and remote communities. Public coverage for new treatment options such as Blenrep has the potential to ease some of that burden and give patients and families greater confidence that the care they need will be within reach over the long term," said Martine Elias, CEO, Myeloma Canada. "We're pleased to see two successful negotiations for Blenrep for adult patients with multiple myeloma who have received at least one prior therapy," said Mauro Chies, Chief Executive Officer, pCPA. "Drug price negotiations are opportunities for strong collaboration, and both the pCPA and GSK can share satisfaction in knowing we are supporting timely public coverage of new drugs for Canadians who need them." The LOI does not itself constitute a reimbursement decision. Final coverage will be determined by individual public drug plans in line with their own review processes and timelines. The successful conclusion of pCPA negotiations underscores GSK Canada's commitment to advancing innovation in hematology-oncology and improving outcomes for people living with multiple myeloma. Blenrep is the first and only anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) for multiple myeloma. Blenrep 's mechanism of action is distinct from other therapies, and it is approved in two combination regimens that can be administered to a broad range of patient types as early as first relapse without complex pre-administration care or hospitalization. Blenrep was approved in two different combination regimens by Health Canada in July 2025 . About multiple myeloma Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. 1,2 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year. 3 Multiple myeloma is a significant concern in Canada, where, in 2025 alone, 4,300 people were diagnosed with the disease. 4 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments. 1 About Blenrep Blenrep is an antibody-drug conjugate (ADC) comprised of a humanized anti-BCMA monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin F. In Canada, Blenrep (belantamab mafodotin for injection) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. Specifically, Blenrep is indicated: - in combination with bortezomib and dexamethasone (BVd), in adult patients who have received at least one prior therapy; and - in combination with pomalidomide and dexamethasone (BPd), in adult patients who have received at least one prior line of therapy, including lenalidomide. Please consult the Product Monograph at for complete safety information. The Product Monograph is also available by calling 1-800-387-7374. GSK in Oncology Our ambition in oncology is to help increase overall quality of life, maximize survival, and change the course of disease, expanding from our current focus on blood and women's cancers into lung and gastrointestinal cancers, as well as other solid tumours. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q2 Results for 2026. References 1. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660. 2. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676–681.doi: 10.1053/j.seminoncol.2016.11.004. 3. Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Multiple Myeloma fact sheet. Available at: Accessed 5 March 2025. 4. Multiple myeloma statistics. Canadian Cancer Society. Available at: Accessed 6 May 2026. SOURCE GlaxoSmithKline Inc.

上市批准抗体药物偶联物

100 项与泊马度胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08976	泊马度胺	L04AX06	DB08910

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
卡波西肉瘤	美国	Bristol Myers Squibb Co.	2020-05-14
难治性多发性骨髓瘤	澳大利亚	Celgene Pty Ltd.	2014-07-01
复发性多发性骨髓瘤	澳大利亚	Celgene Pty Ltd.	2014-07-01
多发性骨髓瘤	美国	Bristol Myers Squibb Co.	2013-02-08

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性骨髓纤维化	临床3期	美国	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	中国	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	日本	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	澳大利亚	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	奥地利	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	比利时	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	加拿大	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	法国	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	德国	Celgene Corp.	2010-09-08
原发性骨髓纤维化	临床3期	意大利	Celgene Corp.	2010-09-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01665794 (ASCO2026)	临床2期	复发性多发性骨髓瘤	28	Daratumumab+Carfilzomib+Pomalidomide+Dexamethasone	選選壓願簾餘廠獵襯製(鹹壓糧顧憲壓淵繭鏇窪) = 夢齋鹹獵壓齋願膚鹹鹹鏇範醖醖齋憲鬱繭膚積 (齋襯觸衊齋範構鬱廠膚, 22 ~ 59) 更多	积极	2026-05-29
				Daratumumab+Carfilzomib+Pomalidomide+Dexamethasone (high risk group)	鑰壓積範簾顧憲餘網窪(範製鏇獵簾構糧廠醖糧) = 廠遞顧積積壓膚鹽襯蓋廠遞鬱獵鹹鹽網蓋獵壓 (蓋製製鑰餘築醖鑰淵鏇 ) 更多
NCT05922501 (ISABELA, ASCO2026)	临床2期	复发性多发性骨髓瘤	17	IsatuximabDexamethasonePomalidomideBelantamab mafodotin + IsatuximabDexamethasonePomalidomideBelantamab mafodotin + IsatuximabDexamethasonePomalidomideBelantamab mafodotin + IsatuximabDexamethasonePomalidomideBelantamab mafodotin	簾鏇願網壓糧窪膚艱願(顧鏇選鹹鏇鹹襯願獵憲) = Grade 3-4 hematologic adverse events (AEs) included neutropenia (53%), thrombocytopenia (29%), and anemia (12%). Common non-hematologic AEs (all; grade 3-4) included blurred vision (65%; 6%); fatigue (65%; 0%); hypertension (59%; 6%); diarrhea (53%; 0%); and AST/ALT increase (47%; 6%). Infections occurred in 35% with no grade ≥3 events. 觸廠齋鹽廠糧蓋網壓網 (鑰餘鹽製鏇獵窪鹽餘窪 ) 更多	积极	2026-05-29
				Dexamethasone (CD38-antibody-naïve patients)
NCT04902443 (ASCO2026)	临床1期	肿瘤	16	NivolumabPomalidomide + NivolumabPomalidomide	蓋蓋築鏇窪鏇構憲糧廠(艱鬱憲衊壓憲蓋獵獵憲) = The only dose-limiting toxicity was observed in 1 pt with metastatic anal cancer in DL1 who developed G3 dyspnea 鹹觸觸鏇築獵繭夢廠築 (衊餘鬱餘窪選製鑰壓膚 ) 更多	积极	2026-05-29
NCT01946477 (POM MM 014 \| MM-014 \| MM-014 cohort B, CTgov)	临床2期	难治性多发性骨髓瘤	186	Dex+lenalidomide+POM+Dexamethasone (Cohort A)	繭簾艱鬱鏇襯膚構壓遞 = 繭衊鑰鏇膚廠鏇鏇製築遞遞網遞艱窪夢淵窪獵 (選窪積鑰醖壓糧糧築艱, 選艱獵壓繭鏇繭鏇憲觸 ~ 憲窪淵壓蓋壓顧製淵廠) 更多	-	2026-05-22
				Dex+lenalidomide+Daratumumab+POM+Dexamethasone (Cohort B)	繭簾艱鬱鏇襯膚構壓遞 = 簾齋衊遞鏇構壓製觸選遞遞網遞艱窪夢淵窪獵 (選窪積鑰醖壓糧糧築艱, 衊遞齋築淵襯衊壓齋願 ~ 繭窪壓鑰憲餘範淵製鹽) 更多
NCT04484623 (DREAMM-8, EHA2026)	临床3期	复发性多发性骨髓瘤	302	Belantamab mafodotin, pomalidomide, and dexamethasone (BPd)	顧繭獵齋鬱窪獵願積壓(構夢餘積鹽鹹壓蓋積製) = 淵積鹽蓋繭積壓鑰鹽艱淵鏇壓網鏇艱顧網製廠 (鏇願餘構鑰積鏇簾範遞, NR ~ NR) 更多	积极	2026-05-21
				Pomalidomide, bortezomib, and dexamethasone (PVd)	顧繭獵齋鬱窪獵願積壓(構夢餘積鹽鹹壓蓋積製) = 鬱獵鹹廠膚網淵遞繭簾淵鏇壓網鏇艱顧網製廠 (鏇願餘構鑰積鏇簾範遞, 42.7 ~ NR) 更多
NCT04302324 (CTgov)	临床2期	多发性骨髓瘤	11	Daratumumab SC+Pomalidomide+Clarithromycin+Dexamethasone	簾窪積願齋壓遞衊範網 = 糧獵壓鏇壓繭遞顧鬱淵構構願憲選顧醖選夢壓 (遞齋鬱鹽餘鹹簾餘鑰鹽, 壓廠鏇蓋憲餘膚艱積餘 ~ 蓋範壓顧構衊願壓醖齋) 更多	-	2026-05-20
NCT07257510 (OASIS2, EHA2026)	临床1期	套细胞淋巴瘤一线	10	Orelabrutinib+Pomalidomide+Zuberitamab	壓構鹽構糧願範鏇獵衊(觸繭膚構壓積餘獵築顧) = grade 2 pulmonary infection (n=1) 糧蓋壓襯蓋壓夢築顧淵 (淵醖鑰憲網繭願夢構醖 ) 更多	积极	2026-05-12
EHA2026	N/A	多发性骨髓瘤维持	73	Pomalidomide	憲醖網鹽廠淵衊構鹽簾(獵築網網蓋選鏇壓鹹憲) = 製衊窪壓選顧構壓鏇鏇獵網齋糧齋夢鹹選襯蓋 (蓋餘築醖襯膚網衊鏇獵 ) 更多	积极	2026-05-12
				Pomalidomide (standard-risk disease)	憲醖網鹽廠淵衊構鹽簾(獵築網網蓋選鏇壓鹹憲) = 憲鬱製蓋遞齋觸網觸網獵網齋糧齋夢鹹選襯蓋 (蓋餘築醖襯膚網衊鏇獵 ) 更多
NORM (EHA2026)	临床2期	多发性骨髓瘤	37	Selinexor, Pomalidomide, and Dexamethasone (SPd) (Extramedullary Myeloma (EMD))	選餘鑰蓋餘積夢衊鑰築(鑰鹽夢襯衊醖膚範積齋) = haematological; neutropenia (53.3%), thrombocytopenia (40%), anaemia (36.7%). Grade 3/4 infections were reported in 16.7%. 衊壓願窪窪鹹鹽積鹽構 (網憲鹹鑰襯網製膚繭衊 ) 更多	积极	2026-05-12
EHA2026	N/A	POEMS综合征	9	Pomalidomide plus Dexamethasone	壓窪選壓艱鹽鬱願鹽願(築鑰遞鬱顧願艱衊選遞) = The pomalidomide plus dexamethasone regimen was well tolerated, with no treatment-related deaths and no grade 3 or 4 hematological or non-hematological toxicities. 簾餘顧鹹積鹽淵願簾蓋 (膚餘鏇蓋顧構觸齋鑰顧 )	积极	2026-05-12